Critical Care Medicine
Pediatric Status Epilepticus
Pediatric Status Epilepticus
GCSE = Generalized Convulsive Status Epilepticus
NCSE = Nonconvulsive Status Epilepticus
RSE = Refractory Status Epilepticus
Neonatal SE = Neonatal Status Epilepticus
AED = Anti-Epileptic Drug
1. Description of the problem
Classical definition: seizure activity (continuous or episodic) without complete recovery of consciousness for > 30 minutes.
Operational definition: seizure activity > 5 minutes and persisting. Intervention should not be delayed as seizures > 5 minutes are unlikely to remit spontaneously, and become less likely to respond as the duration increases.
For the ICU, status epilepticus can be considered as convulsive (GCSE) or nonconvulsive (NCSE). Refractory status epilepticus (RSE) = SE that persists after adequate doses of two anticonvulsants. Neonatal SE is difficult to diagnose and treat as neonatal seizures are frequently poorly organized and polymorphic and may require alternative treatment approaches.
nearly 80% of pediatric SE can be tonic, clonic, or tonic-clonic seizure activity that involves all extremities.
continuous nonmotor seizures
requires EEG for diagnosis
may occur in ambulatory (e.g. absence) or comatose patients
may be difficult to diagnose. Should be considered with prolonged obtundation after seizure cessation or with coma of unclear etiology
diagnosis requires high degree of suspicion. Probably under-recognized
more common in younger children (1 month to 1 year of age)
2. Emergency Management
SE is a medical emergency that requires prompt intervention and stabilization.
Seizure duration inversely associated with treatment responsiveness and favorable outcome.
Management directed to
rapid cessation of seizures
treatment of causal or underlying conditions
prevention of seizure recurrence
First priority is to ensure airway patency and control.
nothing placed in patient's mouth due to risk for aspiration
supplemental oxygen should be provided and respirations assisted as needed
consider RSI for airway protection with hypoxia, hypoventilation, GCS < 8, or concern for aspiration
Position patient so that ongoing seizure activity will not cause physical harm.
Establish IV access ASAP. Consider IO.
Isotonic IVF resuscitation for hypotension or dehydration. Avoid hypotonic solutions.
Do not treat hypertension (which is common with seizure activity). This may be maintaining cerebral perfusion.
Consider hypoglycemia as etiology. In absence of rapid testing, consider empiric dextrose intravenous treatment.
Consider thiamine (50-100 mg IV) prior to dextrose administration in older children at risk of nutritional deficiencies.
Consider electrolyte abnormalities (hyponatremia, hypocalcemia).
High-dose antibiotics should be empirically given to patients at risk of bacterial infection or those with new-onset seizure and fever. Acyclovir if at risk for herpetic infection.
Medications for termination of seizures
Rapid cessation of SE associated with improved response rates and clinical outcomes.
recommended dose 0.05-0.1 mg/kg
first-line treatment for all types of convulsive SE except neonatal SE (for which it is second-line)
peak effect at 15 minutes, duration of action is 3-6 hours
if 1st dose not effective, 2nd dose recommended before or concurrent with 2nd line agent.
less favorable than lorazepam: Shorter duration = 15-30 minutes
less favorable than lorazepam: Shorter duration = 30-80 minutes
metabolized by cytochrome P450 enzymes: may have variable metabolism and more drug interactions
Diazepam per rectum
0.2-0.5 mg/kg PR
for prehospital care or without IV access
bioavailability ~ 90%
peak effect at 1.5 hours
0.1-0.15 mg/kg; max 0.5 mg/kg)
~90% bioavailability and rapidly absorbed
average onset 2-3 minutes, peak at 30 minutes
0.3 mg/kg of IV formulation between gum and cheek
administration is easy and safe. May be more efficacious than rectal diazepam
0.2-0.5 mg/kg; max 0.5 mg/kg
second line agent for kids > 1 year old
dose 20 phenytoin equivalents per kg - infuse over 6 minutes
if 2nd dose needed, may give 10 phenytoin equivalents over 6 minutes
Swift cessation of seizures is primary goal. Anticonvulsant therapy and patient stabilization should not be delayed to facilitate diagnostic testing.
Blood and urine tests
serum glucose and electrolyte testing
serum anticonvulsant medication levels in children on chronic therapy
blood and urine specimens for culture, especially in febrile patients
serum and urine toxicology testing (for possible ingestions)
serum ammonia, lactate, and serum amino and urine organic acid levels should be checked in infants and children at risk for inborn errors of metabolism
Head CT scan
only after seizures controlled
appropriate with new-onset seizures to those at risk for anatomic abnormalities, mass intracranial lesions, or cerebral edema
only after mass intracranial lesion or cerebral edema excluded, AND seizure activity is controlled
indicated in patients at risk for meningitis or with a new-onset seizure
avoid in patients with evidence or risk for increased ICP, due to risk for downward herniation.
4. Specific Treatment
Pediatric Acute and Prolonged Seizure Treatment Algorithm
5. Disease monitoring, follow-up and disposition
Incidence of status epilepticus in children aged 1 month to 16 years is 17-38 per 100,000 individuals per year.
> 40% of pediatric SE is in children < 2 years old.
Overall mortality rates range between 3-7.2%.
Special considerations for nursing and allied health professionals.
What's the evidence?
Rogers’ Textbook of Pediatric Intensive Care. Editor David Nichols.
Abend, N, Dlugos, D. "Treatment of Refractory Status Epilepticus: Literature Review and a Proposed Protocol". Pediatric Neurology. vol. 38. 2008. pp. 377-90.
Raj, D, Gulati, S, Lodha, R. "Status Epilepticus". Indian J Pediatr. vol. 78. 2011. pp. 219-226.
Poukas, VS, Pollard, JR, Anderson, CT. "Rescue Therapies for Seizures". Curr Neurol Neurosci Rep. vol. 11. 2011. pp. 418-22.
Wermeling, DP. "Intranasal Delivery of Antiepileptic Medications for Treatment of Seizures". Neurotherapeutics. vol. 6. 2009. pp. 352-58.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|